Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Q4 2025 value amounting to $2.1 million.

  • Arrowhead Pharmaceuticals' Capital Expenditures fell 7142.1% to $2.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $17.3 million, marking a year-over-year decrease of 7842.37%. This contributed to the annual value of $22.7 million for FY2025, which is 8395.41% down from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Capital Expenditures is $2.1 million, which was down 7142.1% from $7.5 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Capital Expenditures high stood at $68.7 million for Q4 2023, and its period low was $2.1 million during Q4 2025.
  • Moreover, its 5-year median value for Capital Expenditures was $8.9 million (2021), whereas its average is $20.8 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Capital Expenditures skyrocketed by 57343.37% in 2022 and then tumbled by 8905.27% in 2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Capital Expenditures (Quarter) stood at $5.8 million in 2021, then surged by 573.43% to $38.9 million in 2022, then soared by 76.44% to $68.7 million in 2023, then plummeted by 89.05% to $7.5 million in 2024, then tumbled by 71.42% to $2.1 million in 2025.
  • Its Capital Expenditures was $2.1 million in Q4 2025, compared to $7.5 million in Q3 2025 and $2.4 million in Q2 2025.